Rct-869- May 2026

The RCT-869 was a multicenter, randomized, double-blind, placebo-controlled trial that enrolled a diverse population of patients with the target condition. The study consisted of a 12-week treatment phase followed by a 24-week follow-up period. Patients were randomly assigned to receive either the investigational product or a placebo, with a 1:1 allocation ratio.

The RCT-869 enrolled a total of 500 patients, with 250 patients in each treatment arm. The study population had a mean age of 45 years, with 55% female and 45% male participants. The results of the study showed that the investigational product significantly improved the primary endpoint, with a 30% greater reduction in symptoms compared to the placebo group (p < 0.001). RCT-869-

The study's primary endpoint was a composite measure of clinical response, which included symptom reduction, quality of life, and functional outcomes. Secondary endpoints included assessments of safety, patient satisfaction, and exploratory analyses of biomarkers. The RCT-869 enrolled a total of 500 patients,